Rawson Krista M, Newburn-Cook Christine V
Cross Cancer Institute, Edmonton, Canada.
Oncol Nurs Forum. 2007 Sep;34(5):1037-43. doi: 10.1188/07.ONF.1037-1043.
PURPOSE/OBJECTIVES: To determine whether the use of low-dose warfarin could reduce the incidence of thrombosis in patients with cancer who have a central venous catheter (CVC).
MEDLINE, CINAHL, CANCERLIT, EMBASE, and the Cochrane Library.
Meta-analysis of four studies (N = 1,236 patients) revealed that 6.4% of warfarin-treated patients experienced a thrombotic event compared with 7.5% in the control (no treatment) group. The risk difference for thrombus formation was not significant (2.0%, confidence interval = -9.0% to 5.0%).
The administration of warfarin did not reduce the incidence of symptomatic or asymptomatic CVC-associated thrombosis in patients with cancer.
Using research findings to inform clinical nursing practice is important in caring for patients and providing optimal and improved patient outcomes. Prophylactic use of low-dose warfarin may not prevent thrombus formation and is associated with potentially adverse patient outcomes.
目的/目标:确定使用低剂量华法林是否可降低患有中心静脉导管(CVC)的癌症患者发生血栓形成的几率。
医学期刊数据库(MEDLINE)、护理学与健康领域数据库(CINAHL)、癌症文献数据库(CANCERLIT)、荷兰医学文摘数据库(EMBASE)以及考科蓝图书馆。
对四项研究(共1236例患者)进行的荟萃分析显示,接受华法林治疗的患者中有6.4%发生了血栓形成事件,而对照组(未治疗)的这一比例为7.5%。血栓形成的风险差异并不显著(2.0%,置信区间为-9.0%至5.0%)。
在患有癌症的患者中,使用华法林并不能降低有症状或无症状的CVC相关血栓形成的发生率。
利用研究结果指导临床护理实践对于护理患者以及提供最佳和改善的患者预后非常重要。预防性使用低剂量华法林可能无法预防血栓形成,且与潜在的不良患者预后相关。